¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)
¼¶±ð: ×ܰæÖ÷
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-01-25   

Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)

Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ @ t8{pb;v  
M5]$w]Ny9  
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© qp ]s VY  
m=]}Tn  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© ?:RWHe.P  
T{ /\q 5  
1.Co-stimulators (or co-stimulating molecules) E^m2:J]G  
vu/P"?F  
2.NK-kB jL~. =QD  
mzTM&@  
3.Immunoglobulin superfamily Wt! NLlN8  
SvD:UG  
4.antigen-presenting cell (APC) Y-*]6:{E  
jiLt *>I  
5.death domain cX48?srG  
Pv3 e*I((  
6.CCR and CXCR =]sM,E,n  
.A <n2-  
7.Lectin (or mitogen) /k^O1+]H  
`,FvYA"  
8.Clusters of differentiation, CD) h)yAg e  
M Y>o8A  
9.B7 family X1lL@`r.5  
eHI7= [h  
10.Cytotoxic T lymphocyte, CTL) +?bOGUik  
>J@hqW  
11.IL-15 and IL-15 receptor (IL-15R) 8'Bik  
OW8"7*irT  
12.MHC restriction 7_AcvsdW  
8E\6RjM  
13.Affinity-chromatography z T#j.v  
KN zm)O  
14.Cyctosprin A, CsA YW)& IA2  
%NfbgJcL_  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) ]abox%U=%  
[|\BuUT'  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© 0p' =Vel{}  
IH0qx_;P&  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 Z 3 $3zyi  
w>$2  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ X3;|h93.a  
dD0:K3@  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ {(!j6|jK  
?Wm.'S'to  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© L|[ 0&u!  
mOvwdRKn  
ÃâÒßѧרҵ£º hZ@Wl6FG;  
@.Pe.\Z  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ 8_@#5  
3<nd;@:-  
Ïû»¯ÄÚ¿Æ£º i-4pdK u  
4^mpQ.]lO  
2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ HO(9 )sK  
8}kY^"*&X  
ѪҺ²¡Ñ§×¨Òµ£º {]w @s7E  
|tU4(hC  
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
4+6=? ÕýÈ·´ð°¸:10
°´"Ctrl+Enter"Ö±½ÓÌá½»